Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor

被引:874
|
作者
Sadler, J. E.
Budde, U.
Eikenboom, J. C. J.
Favaloro, E. J.
Hill, F. G. H.
Holmberg, L.
Ingerslev, J.
Lee, C. A.
Lillicrap, D.
Mannucci, M.
Mazurier, C.
Meyer, D.
Nichols, W. L.
Nishino, M.
Peake, I. R.
Rodeghiero, F.
Schneppenheim, R.
Ruggeri, Z. M.
Srivastava, A.
Montgomery, R. R.
Federici, A. B.
机构
[1] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA
[2] Lab Assoc Prof Arndt & Partners, Hamburg, Germany
[3] Leiden Univ, Med Ctr, Dept Haematol, Leiden, Netherlands
[4] Westmead Hosp, ICPMR, Westmead, NSW 2145, Australia
[5] Birmingham Childrens Hosp NHS Trust, Dept Haematol, Birmingham, W Midlands, England
[6] Univ Lund Hosp, Dept Pediat, S-22185 Lund, Sweden
[7] Univ Hosp Skejby, Dept Clin Immunol, Aarhus, Denmark
[8] Royal Free Hosp, Haemophilia Ctr, London NW3 2QG, England
[9] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada
[10] IRCCS Maggiore Policlin Hosp, Angelo Bianchi Bonomi Hemophilia Thrombosis Ctr, Dept Med Specialties, Milan, Italy
[11] Regina Elena Fdn, Milan, Italy
[12] Univ Milan, Milan, Italy
[13] Lab Srancais Fractionnement & Biotechnol, Lille, France
[14] Hop Bicetre, INSERM, U770, Le Kremlin Bicetre, France
[15] Mayo Clin, Div Hematol & Internal Med, Rochester, MN USA
[16] Nara Prefectural Nara Hosp, Dept Pediat, Nara, Japan
[17] San Bortolo Hosp, Dept Haematol, Hemophilia & Thrombosis Ctr, Vicenza, Italy
[18] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Hamburg, Germany
[19] Scripps Res Inst, Roon Res Lab Arteriosclerosis & Thrombosis, La Jolla, CA USA
[20] Christian Med Coll & Hosp, Dept Hematol, Vellore, Tamil Nadu, India
[21] Blood Res Inst, Milwaukee, WI USA
关键词
ADAMTS-13; classification; pathophysiology; von Willebrand disease;
D O I
10.1111/j.1538-7836.2006.02146.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
von Willebrand disease (VWD) is a bleeding disorder caused by inherited defects in the concentration, structure, or function of von Willebrand factor (VWF). VWD is classified into three primary categories. Type 1 includes partial quantitative deficiency, type 2 includes qualitative defects, and type 3 includes virtually complete deficiency of VWF. VWD type 2 is divided into four secondary categories. Type 2A includes variants with decreased platelet adhesion caused by selective deficiency of high-molecular-weight VWF multimers. Type 2B includes variants with increased affinity for platelet glycoprotein Ib. Type 2M includes variants with markedly defective platelet adhesion despite a relatively normal size distribution of VWF multimers. Type 2N includes variants with markedly decreased affinity for factor VIII. These six categories of VWD correlate with important clinical features and therapeutic requirements. Some VWF gene mutations, alone or in combination, have complex effects and give rise to mixed VWD phenotypes. Certain VWD types, especially type 1 and type 2A, encompass several pathophysiologic mechanisms that sometimes can be distinguished by appropriate laboratory studies. The clinical significance of this heterogeneity is under investigation, which may support further subdivision of VWD type 1 or type 2A in the future.
引用
收藏
页码:2103 / 2114
页数:12
相关论文
共 50 条
  • [41] Von Willebrand Factor Multimeric Assay in Acquired von Willebrand Disease Diagnosis: A Report of Experience from North Estonia Medical Centre
    Pikta, Marika
    Banys, Valdas
    Szanto, Timea
    Joutsi-Korhonen, Lotta
    Vaide, Ines
    Varik, Mirja
    Lehtinen, Anna-Elina
    Giangrande, Paul
    Laane, Edward
    JOURNAL OF LABORATORY PHYSICIANS, 2021, 13 (03) : 195 - 201
  • [42] A Comparative Evaluation of an Automated Functional Assay for Von Willebrand Factor Activity in Type 1 Von Willebrand Disease
    Lai, Shiue-Wei
    Chang, Chia-Yau
    Cheng, Shin-Nan
    Hu, Shu-Hsia
    Lai, Chung-Yu
    Chen, Yeu-Chin
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 5167 - 5174
  • [43] Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Haemate P) in von Willebrand Disease: A Systematic Review and Pharmacovigilance Update
    Ettingshausen, Carmen Escuriola
    Lassila, Riitta
    Escolar, Gines
    Male, Christoph
    Schirner, Kathrin
    Heyder, Lisa
    Berntorp, Erik
    HAEMOPHILIA, 2025, 31 (02) : 247 - 262
  • [44] Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis
    James, A. H.
    Konkle, B. A.
    Kouides, P.
    Ragni, M. V.
    Thames, B.
    Gupta, S.
    Sood, S.
    Fletcher, S. K.
    Philipp, C. S.
    HAEMOPHILIA, 2015, 21 (01) : 81 - 87
  • [45] Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease
    Sukhu, K
    Poovalingam, V
    Mahomed, R
    Giangrande, PLF
    CLINICAL AND LABORATORY HAEMATOLOGY, 2003, 25 (04): : 247 - 249
  • [46] Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease
    Stufano, Francesca
    Baronciani, Luciano
    Bucciarelli, Paolo
    Boscarino, Marco
    Colpani, Paola
    Pagliari, Maria Teresa
    Peyvandi, Flora
    HAEMOPHILIA, 2020, 26 (02) : 298 - 305
  • [47] Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease
    Gill, Joan C.
    Castaman, Giancarlo
    Windyga, Jerzy
    Kouides, Peter
    Ragni, Margaret
    Leebeek, Frank W. G.
    Obermann-Slupetzky, Ortrun
    Chapman, Miranda
    Fritsch, Sandor
    Pavlova, Borislava G.
    Presch, Isabella
    Ewenstein, Bruce
    BLOOD, 2015, 126 (17) : 2038 - 2046
  • [48] Increase of von Willebrand factor with aging in type 1 von Willebrand disease: fact or fiction?
    Borghi, Mariachiara
    Guglielmini, Giuseppe
    Mezzasoma, Anna Maria
    Falcinelli, Emanuela
    Bury, Loredana
    Malvestiti, Marco
    Gresele, Paolo
    HAEMATOLOGICA, 2017, 102 (11) : E431 - E433
  • [49] Toward Personalized Treatment for Patients with Low von Willebrand Factor and Quantitative von Willebrand Disease
    O'Donnell, James S.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2021, 47 (02) : 192 - 200
  • [50] Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease
    Franchini, Massimo
    Mannucci, Pier Mannuccio
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (09) : 825 - 830